FEDERICO
PULIDO ORTEGA
Profesor asociado de Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublications in collaboration with researchers from Hospital Universitario 12 de Octubre (200)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians
The Lancet HIV, Vol. 11, Núm. 5, pp. e333-e340
2023
-
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
HIV Medicine, Vol. 24, Núm. 1, pp. 27-36
-
Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis
Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114
-
Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))
eBioMedicine
-
Deep Sequencing on Proviral DNA: More Questions than Answers
Journal of acquired immune deficiency syndromes (1999)
-
Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 149-154
2022
-
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
PLoS ONE, Vol. 17, Núm. 11 November
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Open Forum Infectious Diseases, Vol. 9, Núm. 11
-
Severe diarrhea by Cystoisospora belli in a well controlled HIV-infected patient
AIDS (London, England), Vol. 36, Núm. 3, pp. 485-486
2021
-
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Infectious Diseases and Therapy, Vol. 10, Núm. 2, pp. 775-788
-
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271
-
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial
AIDS Research and Human Retroviruses, Vol. 37, Núm. 3, pp. 207-213
-
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals
Liver International, Vol. 41, Núm. 12, pp. 2885-2891
-
Late HIV diagnosis among immigrants in Spain vs. native-born Spaniards, 2010-15
European Journal of Public Health, Vol. 31, Núm. 6, pp. 1123-1128
-
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684
-
Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study
BMC Infectious Diseases, Vol. 21, Núm. 1
-
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Journal of acquired immune deficiency syndromes (1999), Vol. 86, Núm. 4, pp. 490-495